Document is current
Any future updates will be listed below
-
Authors
Triska, Jeffrey https://orcid.org/0000-0003-4476-7994
Tamargo, Juan
Bozkurt, Biykem
Elkayam, Uri
Taylor, Addison
Birnbaum, Yochai
-
Funding
Funding for this research was provided by:
John S. Dunn Foundation
Comunidad de Madrid (B2017/BMD-3738)
- License Information
-
More Information
Article History
Accepted: 24 March 2022
First Online: 31 March 2022
Declarations
:
: Jeffrey Triska—None.Juan Tamargo—None.Biykem Bozkurt—In regard to beta-blockers, consulting fees from Bristol Myers Squibb, scPharmaceuticals Inc., Baxter Healthcare Corporation, Sanofi-Aventis, Relypsa, Amgen and serves on the Clinical Event Committee for <i>Haemodynamic-guided management of heart failure</i> (GUIDE-HF) trial sponsored by Abbott Vascular, and Data Safety Monitoring Committee of Autonomic <i>REGULATION Therapy to Enhance Myocardial Function and Reduce progression of Heart Failure with reduced ejection fraction</i> (ANTHEM) sponsored by Liva Nova.Uri Elkayam—None.Addison Taylor—None.Yochai Birnbaum—Research grant from AstraZeneca for ticagrelor and dapagliflozin.
